A New, AI-Augmented Horizon For Safety And Pharmacovigilance: Expert Predictions For 2026

By Ian Fisher, Michelle Gyzen, Archana Hegde, Ana Pedro Jesuíno, and Louise Molloy

As AI workflows become the new normal across the pharmaceutical industry, drug sponsors, technology vendors, regulators, and other stakeholders must collaborate to integrate this technology and maintain regulatory compliance. Amid these exciting changes, organizations are exploring how AI fits into existing safety and regulatory workflows; how best to prepare staff to understand, implement, and monitor such technology; and how to uphold regulatory standards amid shifting global guidance.

In a recent panel discussion, five experts from IQVIA sat down to discuss the biggest changes they saw to safety and regulatory workflows in 2025 and what we can look forward to in 2026. Their wide-ranging discussion touched on everything from the importance of keeping humans-in-the-loop during AI-assisted workflows to the role of AI governance in maintaining compliance. Download the full article to explore the latest trends on the horizon and how best to prepare your staff for this major technology upgrade.